Vectibix® and best supportive care improves overall survival in mCRC

First Phase III Vectibix trial to include a prespecified analysis of efficacy endpoints by RAS tumour status in primary analysis. Results presented at Gastrointestinal Cancers Symposium 2016 reinforce importance of RAS testing

Source: Pharmacy Europe - January 25, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Other conferences & symposia Gastroenterology Oncology Patient care Research amgen best supportive care exon 2 gastrointestinal cancers symposium 2016 kras Latest News Source Type: news